Valion Bio (VBIO) Stock Insights
VBIO$0.63-0.05 -6.67%
$1.33M
Market Cap
—
P/E
—
Forward P/E
—
Score
VBIO price $0.63 -0.05 -6.67%
Valion Bio, Inc. operates as a late-stage biopharmaceutical company. Its lead drug candidate is Entolimod, a TLR5 agonist that is in late-stage development to treat acute radiation syndrome. The company's pipeline also comprises Entolimod to treat Neutropenia and lymphocyte exhaustion; and Entolasta, an immunologically optimized variant of Entolimod for chronic applications, such as immunosenescence. In addition, it…
Insights · Dividends · Forecast · Financials · Learn
$1.33M
Market Cap
—
P/E
—
Forward P/E
—
Score